α-MSH	alpha-melanocyte-stimulating hormone
ACTH	adrenocorticotropic hormone
Ad-MAGEA3	adenovirus vaccine expressing melanoma-associated antigen 3
AEs	adverse events
AK	actinic keratoses
allo-HCT	allogeneic hematopoietic stem cell transplantation
ASIP	agouti signaling protein
BCC	basal cell carcinoma
BID	twice daily
CI	confidence interval
CM	cutaneous melanoma
CR	complete response
cSCC	cutaneous squamous cell carcinoma
CTCL	cutaneous T cell lymphoma
CTL	cytotoxic T lymphocyte
DCR	disease control rate
DoR	duration of response
EAP	expanded access program
EGFR	epidermal growth factor receptor
EMA	European Medicines Agency
FDA	U.S. Food and Drug Administration
FGF	fibroblast growth factor
GVHD	graft-versus-host disease
Gy	Gray
HGF	hepatocyte growth factor
HNSCC	head and neck squamous cell carcinoma
i.m.	intramuscular
i.t.	intratumoral
i.v.	intravenous
ICB	immune checkpoint blockade
laSCC	locally advanced cSCC
MC1R	melanocortin 1 receptor
MG1-MAGEA3	MG1 Maraba oncolytic virus expressing melanoma-associated antigen 3
mSCC	metastatic cSCC
NER	nucleotide excision repair
NMSC	non-melanoma skin cancer
NSCLC	non-small cell lung cancer
ORR	objective response rate
OS	overall survival
OTR	organ transplant recipient
PD	progressive disease
PFS	progression-free survival
PR	partial response
POMC	proopiomelanocortin
PYs	person-years
Q2W	every 2 weeks
Q3W	every 3 weeks
Q4W	every 4 weeks
Q6W	every 6 weeks
QD	daily
QoL	quality of life
QW	every week
RCT	randomized-controlled trial
RFS	recurrence free survival
rhIL-7-hyFc	recombinant human interleukin-7 and hybrid Fc fusion protein
RP1	genetically modified herpes simplex virus 1
RR	response rate
SCF	stem cell factor
SD	stable disease
T-VEC	talimogene laherparepvec
XP	xeroderma pigmentosum